Yanguang Cao

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 33

Top Topics

Ankylosing Spondylitis

Metastatic Colorectal Cancer

Regulatory T Cells

Top Venues

PLoS computational biology

Clinical pharmacology and therapeutics

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaozhi Liao, Timothy Qi, Jiawei Zhou, Can Liu, Yanguang Cao
Optimizing Clinical Translation of Bispecific T-cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model. Clinical pharmacology and therapeutics (2024)
Prathap Nagaraja Shastri, Nirav Shah, Martin Lechmann, Hardik Mody, Marc W Retter, Min Zhu, Tommy Li, Jun Wang, Naveed Shaik, Xirong Zheng, Meric Ovacik, Fei Hua, Vibha Jawa, Christophe Boetsch, Yanguang Cao, John Burke, Kaushik Datta, Kapil Gadkar, Vijay Upreti, Alison Betts
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy. Clinical pharmacology and therapeutics (2024)
Xiaozhi Liao, Timothy Qi, Jiawei Zhou, Can Liu, Yanguang Cao
Optimizing Clinical Translation of Bispecific T-cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model. Clinical pharmacology and therapeutics 116 (2) (2024)
Xiaozhi Liao, Timothy Qi, Jiawei Zhou, Can Liu, Yanguang Cao
Optimizing Clinical Translation of Bispecific T-cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model. Clinical pharmacology and therapeutics 116 (2) (2024)
Xiaozhi Liao, Timothy Qi, Jiawei Zhou, Can Liu, Yanguang Cao
Optimizing Clinical Translation of Bispecific T-cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model. Clinical pharmacology and therapeutics 116 (2) (2024)
Jiawei Zhou, Amber B Cipriani, Yutong Liu, Gang Fang, Quefeng Li, Yanguang Cao
Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. Nature communications 14 (1) (2023)
Jiawei Zhou, Amber B Cipriani, Yutong Liu, Gang Fang, Quefeng Li, Yanguang Cao
Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. Nature communications 14 (1) (2023)
Can Liu, Jiawei Zhou, Stephan T Kudlacek, Timothy Qi, Tyler Dunlap, Yanguang Cao
Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance. eLife 12 (2023)
Timothy Qi, Benjamin Vincent, Yanguang Cao
A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. PLoS computational biology 19 (4) (2023)
Wei Gao, Jiang Liu, Blerta Shtylla, Karthik Venkatakrishnan, Donghua Yin, Mirat Shah, Timothy Nicholas, Yanguang Cao
Realizing the Promise of Project Optimus: Challenges and Emerging Opportunities for Dose Optimization in Oncology Drug Development. CPT: pharmacometrics & systems pharmacology (2023)
Timothy Qi, Benjamin G Vincent, Yanguang Cao
A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. PLoS computational biology 19 (4) (2023)
Milica Markovic, Jelica Milošević, Weirong Wang, Yanguang Cao
Passive Immunotherapies Targeting Amyloid-β in Alzheimer's Disease: A Quantitative Systems Pharmacology Perspective . Molecular pharmacology (2023)
Timothy Qi, Benjamin Vincent, Yanguang Cao
A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. PLoS computational biology 19 (4) (2023)
Timothy Qi, Benjamin G Vincent, Yanguang Cao
A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. PLoS computational biology 19 (4) (2023)
Timothy Qi, Benjamin G Vincent, Yanguang Cao
A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. PLoS computational biology 19 (4) (2023)
Jiawei Zhou, Amber B Cipriani, Yutong Liu, Gang Fang, Quefeng Li, Yanguang Cao
Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. Nature communications 14 (1) (2023)
Kaitlyn Maffuid, Yanguang Cao
Utilizing a Proximity Dependent Labeling Strategy to Study Cancer-Immune Intercellular Interactions In Vitro and In Vivo . The Journal of pharmacology and experimental therapeutics (2023)
Timothy Qi, Benjamin Vincent, Yanguang Cao
A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. PLoS computational biology 19 (4) (2023)
Jiawei Zhou, Amber B Cipriani, Yutong Liu, Gang Fang, Quefeng Li, Yanguang Cao
Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. Nature communications 14 (1) (2023)
Kaitlyn Maffuid, Yanguang Cao
Decoding the Complexity of Immune-Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy. Cancers 15 (16) (2023)
Timothy Qi, Benjamin G Vincent, Yanguang Cao
A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. PLoS computational biology 19 (4) (2023)
Timothy Qi, Tyler Dunlap, Yanguang Cao
Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology? Pharmaceutical research (2022)
Eric Salgado, Yanguang Cao
A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph Nodes. Antibodies (Basel, Switzerland) 11 (2) (2022)
Jiawei Zhou, Quefeng Li, Yanguang Cao
Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer. Cancer research 81 (9) (2021)
Ziqiang Li, Xi Du, Yanfen Li, Ruihua Wang, Changxiao Liu, Yanguang Cao, Weidang Wu, Jinxia Sun, Baohe Wang, Yuhong Huang
Pharmacokinetics of gallic acid and protocatechuic acid in humans after dosing with Relinqing (RLQ) and the potential for RLQ-perpetrated drug-drug interactions on organic anion transporter (OAT) 1/3. Pharmaceutical biology 59 (1) (2021)
Timothy Qi, Yanguang Cao
In Translation: FcRn across the Therapeutic Spectrum. International journal of molecular sciences 22 (6) (2021)
Anne M Talkington, Timothy Wessler, Samuel K Lai, Yanguang Cao, M Gregory Forest
Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery. Bulletin of mathematical biology 83 (12) (2021)
Yu Tang, Yanguang Cao
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics 13 (3) (2021)
Hua He, Dongfen Yuan, Yun Wu, Yanguang Cao
Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs. Pharmaceutics 11 (3) (2019)
Jiawei Zhou, Yutong Liu, Yubo Zhang, Quefeng Li, Yanguang Cao
Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. Cancer research 80 (3) (2019)
Hua He, Can Liu, Yun Wu, Xinyuan Zhang, Jianghong Fan, Yanguang Cao
A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts. Pharmaceutical research 35 (9) (2018)
Brian M Maas, Yanguang Cao
A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species. mAbs 10 (8) (2018)
Xiaobing Li, William J Jusko, Yanguang Cao
Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model. The Journal of pharmacology and experimental therapeutics 367 (1) (2018)